Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript
Summarize this article with:
SA Transcripts157.41K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma December 18, 2025 8:30 AM EST Company Participants Alex Kane - Senior Vice President of Investor Relations & Capital MarketsLara Sullivan - CEO, President, Chief Medical Officer & Director Conference Call Participants Bradley Canino - Guggenheim Securities, LLC, Research DivisionFarzin Haque - Jefferies LLC, Research DivisionSamuel Slutsky - LifeSci Capital, LLC, Research DivisionJeffrey LaRosa - Leerink Partners LLC, Research DivisionStephen Willey - Stifel, Nicolaus & Company, Incorporated, Research DivisionSudan Loganathan - Stephens Inc., Research DivisionSwayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research DivisionTsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to Pyxis Oncology MICVO Clinical Update Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to turn the conference over to Alex Kane, Senior Vice President of Investor Relations and Capital Markets. Please go ahead. Alex KaneSenior Vice President of Investor Relations & Capital Markets Hi, and good morning, everyone. My name is Alex Kane, and I'm the Senior Vice President of Investor Relations and Capital Markets at Pyxis Oncology. Thank you all for joining us on the phone and webcast today to discuss the MICVO recurrent metastatic head and neck squamous cell carcinoma clinical update. Our President, CEO and CMO, Lara Sullivan, will review prepared remarks, followed by a Q&A session that will include Lara and additional members of the team. We will be making certain forward-looking statements throughout today's discussion. I would recommend that you read the SEC filings, including our forward-looking statement disclosure and related risk factors in our recent Form 10-Q. With that, I will pass the call over to Lara to